New drug takes aim at Hard-to-Treat blood cancers
NCT ID NCT04830137
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests a new oral drug called NX-2127 in adults with advanced B-cell cancers (like certain leukemias and lymphomas) that have not responded to standard treatments. The drug works by breaking down a protein that helps cancer cells grow. The main goals are to check safety, find the right dose, and see if it shrinks tumors. About 248 people will take part.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
NX-2127 (a drug that breaks down a protein called BTK to help fight cancer)
What this could lead to
If it works, this could offer a new treatment option for people with advanced B-cell cancers that have stopped responding to other therapies.
What could go wrong
This is a very early Phase 1 trial, so the drug may not work or could have serious side effects. It is only for patients who have already tried other treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FOLLICULAR LYMPHOMA (FL) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Baylor University Medical Center
COMPLETEDDallas, Texas, 75246, United States
-
City of Hope
RECRUITINGDuarte, California, 91010, United States
-
Huntsman Cancer Institute, University of Utah
RECRUITINGSalt Lake City, Utah, 84112, United States
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
-
Memorial Sloan Kettering Cancer Center
COMPLETEDNew York, New York, 10065, United States
-
Mount Sinai Comprehensive Cancer Center
COMPLETEDMiami Beach, Florida, 33140, United States
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20814, United States
-
OSU Wexner Medical Center
COMPLETEDColumbus, Ohio, 43210, United States
-
Sarah Cannon Research Institute at Colorado Blood Cancer Institute
RECRUITINGDenver, Colorado, 80218, United States
-
Sarah Cannon Research Institute at Florida Cancer Specialists
COMPLETEDSarasota, Florida, 34203, United States
-
Swedish Cancer Institute
COMPLETEDSeattle, Washington, 98104, United States
-
Tennessee Oncology
RECRUITINGNashville, Tennessee, 37203, United States
-
The University of Chicago Medical Center
RECRUITINGChicago, Illinois, 60637, United States
-
University of California Irvine
COMPLETEDOrange, California, 92868, United States
-
University of California San Francisco Medical Center
COMPLETEDSan Francisco, California, 94143, United States
-
University of Cincinnati Medical Center
COMPLETEDCincinnati, Ohio, 45267, United States